User profiles for Timothy Wong

Timothy C Wong, MD MS

University of Pittsburgh School of Medicine, Medicine, Cardiology; UPMC Heart and …
Verified email at upmc.edu
Cited by 3741

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

…, A Turer, O Wever-Pinzon, M Wheeler, T Wong… - The Lancet, 2020 - thelancet.com
Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (…

[HTML][HTML] Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a systemic review and comparison of clinical presentation and …

TL Wong, DJ Weitzer - Medicina, 2021 - mdpi.com
Background and Objectives: Long COVID defines a series of chronic symptoms that patients
may experience after resolution of acute COVID-19. Early reports from studies with patients …

Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality

TC Wong, K Piehler, CG Meier, SM Testa, AM Klock… - Circulation, 2012 - Am Heart Assoc
Background— Extracellular matrix expansion may be a fundamental feature of adverse
myocardial remodeling, it appears to be treatable, and its measurement may improve risk …

Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart …

TC Wong, KM Piehler, IA Kang, A Kadakkal… - European heart …, 2014 - academic.oup.com
Aims Diabetes may promote myocardial extracellular matrix (ECM) expansion that
increases vulnerability. We hypothesized that: (i) type 2 diabetes would be associated with …

Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy

…, A Wang, O Wever-Pinzon, TC Wong… - Journal of the American …, 2020 - jacc.org
Background Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience
a high burden of symptoms; however, there are no proven pharmacological therapies. …

[HTML][HTML] Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus …

…, D Schwartzman, SG Shroff, TC Wong - Journal of …, 2011 - Elsevier
Background Myocardial extravascular extracellular volume fraction (Ve) measures quantify
diffuse fibrosis not readily detectable by conventional late gadolinium (Gd) enhancement (…

Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection …

…, J Butler, M Gheorghiade, TC Wong - Journal of the …, 2015 - Am Heart Assoc
Background Myocardial fibrosis ( MF ) in noninfarcted myocardium may be an interstitial
disease pathway that confers vulnerability to hospitalization for heart failure, death, or both …

CCCTC-binding factor (CTCF) and cohesin influence the genomic architecture of the Igh locus and antisense transcription in pro-B cells

SC Degner, J Verma-Gaur, TP Wong… - Proceedings of the …, 2011 - National Acad Sciences
Compaction and looping of the ~2.5-Mb Igh locus during V(D)J rearrangement is essential
to allow all V H genes to be brought in proximity with D H -J H segments to create a diverse …

The bases of political trust in six Asian societies: Institutional and cultural explanations compared

TK Wong, P Wan, HHM Hsiao - … Political Science Review, 2011 - journals.sagepub.com
Political trust reflects people’s evaluative orientation toward the polity and is thus vital to
regime stability. Based on data drawn from a cross-national social survey, this article examines …

Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy

…, R Barriales-Villa, CM Kramer, TC Wong… - Journal of the American …, 2023 - jacc.org
Background Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart
failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-…